These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 20116439)

  • 1. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
    Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.
    Zhao F; Zhang Y; Wang H; Jin M; He S; Shi Y; Guo Y; Zhang Y
    Blood; 2011 Feb; 117(5):1723-33. PubMed ID: 21119110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells.
    Yu XZ; Liang Y; Nurieva RI; Guo F; Anasetti C; Dong C
    J Immunol; 2006 Jun; 176(12):7394-401. PubMed ID: 16751384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
    Capitini CM; Nasholm NM; Duncan BB; Guimond M; Fry TJ
    J Immunol; 2013 Feb; 190(3):1351-9. PubMed ID: 23275602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
    Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
    J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells.
    Yu XZ; Albert MH; Anasetti C
    J Immunol; 2006 Mar; 176(6):3383-90. PubMed ID: 16517706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells.
    Sandy AR; Chung J; Toubai T; Shan GT; Tran IT; Friedman A; Blackwell TS; Reddy P; King PD; Maillard I
    J Immunol; 2013 Jun; 190(11):5818-28. PubMed ID: 23636056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
    Wang J; Li L; Xu M; Rong R; Zhu T
    Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
    Sato M; Storb R; Loretz C; Stone D; Mielcarek M; Sale GE; Rezvani AR; Graves SS
    Transplantation; 2013 Jul; 96(1):34-41. PubMed ID: 23694952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.
    He S; Xie F; Liu Y; Tong Q; Mochizuki K; Lapinski PE; Mani RS; Reddy P; Mochizuki I; Chinnaiyan AM; Mineishi S; King PD; Zhang Y
    Blood; 2013 Dec; 122(25):4119-28. PubMed ID: 24141370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.
    Nellore A; Liu B; Patsoukis N; Boussiotis VA; Li L
    Clin Immunol; 2014; 152(1-2):48-57. PubMed ID: 24631965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
    Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease.
    Li X; Deng R; He W; Liu C; Wang M; Young J; Meng Z; Du C; Huang W; Chen L; Chen Y; Martin P; Forman S; Zeng D
    J Immunol; 2012 Jan; 188(2):724-34. PubMed ID: 22156590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. During acute graft versus host disease CD28 deletion in donor CD8
    Uri A; Lühder F; Kerkau T; Beyersdorf N
    Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.
    Zhang Y; Sandy AR; Wang J; Radojcic V; Shan GT; Tran IT; Friedman A; Kato K; He S; Cui S; Hexner E; Frank DM; Emerson SG; Pear WS; Maillard I
    Blood; 2011 Jan; 117(1):299-308. PubMed ID: 20870902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease.
    Muriglan SJ; Ramirez-Montagut T; Alpdogan O; Van Huystee TW; Eng JM; Hubbard VM; Kochman AA; Tjoe KH; Riccardi C; Pandolfi PP; Sakaguchi S; Houghton AN; Van Den Brink MR
    J Exp Med; 2004 Jul; 200(2):149-57. PubMed ID: 15249593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.
    Liu K; Anthony BA; Yearsly MM; Hamadani M; Gaughan A; Wang JJ; Devine SM; Hadley GA
    PLoS One; 2011; 6(7):e21968. PubMed ID: 21779359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.
    Huang Q; He S; Tian Y; Gu Y; Chen P; Li C; Huang J; Liu Y; Yu H; Jin M; Hu S; Tong Q; Ma A; Jin J; Hexner E; Fung H; Reshef R; Zhang Y; Zhang Y
    Blood; 2017 May; 129(20):2737-2748. PubMed ID: 28246193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.